Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR3”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04003610
What this trial is testing

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Who this might be right for
Metastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
Incyte Corporation 7
Testing effectiveness (Phase 2)Study completedNCT02824133
What this trial is testing

Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"

Who this might be right for
Recurrent IDHwt Gliomas With FGFR3-TACC3 FusionRecurrent IDHwt Gliomas With FGFR1-TACC1 Fusion
Assistance Publique - Hôpitaux de Paris 14
Testing effectiveness (Phase 2)Looking for participantsNCT04153422
What this trial is testing

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Who this might be right for
Small Fiber NeuropathyAutoimmune Small Fiber NeuropathyInflammatory Polyneuropathy+1 more
Endeavor Health 20
Not applicableStudy completedNCT04035811
What this trial is testing

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 271
Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208
Testing effectiveness (Phase 2)Looking for participantsNCT07265947
What this trial is testing

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Who this might be right for
Low Grade Upper Tract Urothelial Carcinoma
Tyra Biosciences, Inc 230
Early research (Phase 1)Looking for participantsNCT06874335
What this trial is testing

BHV-1530 in Advanced Solid Tumors

Who this might be right for
Solid Tumor
Biohaven Therapeutics Ltd. 140
Large-scale testing (Phase 3)Enrolling By InvitationNCT06873035
What this trial is testing

An Interventional Study of Infigratinib in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 24
Early research (Phase 1)Study completedNCT02529553
What this trial is testing

LY3076226 in Participants With Advanced or Metastatic Cancer

Who this might be right for
Advanced CancerMetastatic Cancer
Eli Lilly and Company 25
Testing effectiveness (Phase 2)Ended earlyNCT03834220
What this trial is testing

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Who this might be right for
Solid Tumor
Debiopharm International SA 63
Large-scale testing (Phase 3)Study completedNCT02965378
What this trial is testing

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR2 Gene Amplification+5 more
SWOG Cancer Research Network 43
Not applicableStudy completedNCT02539329
What this trial is testing

Characterization of Anti-FGFR3 Antibodies

Who this might be right for
Sensory Peripheral Neuropathy
Centre Hospitalier Universitaire de Saint Etienne 251
Not applicableUnknownNCT00126958
What this trial is testing

Cost-Effectiveness in Bladder Cancer

Who this might be right for
Bladder Cancer
Erasmus Medical Center 500
Testing effectiveness (Phase 2)Ended earlyNCT02401542
What this trial is testing

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

Who this might be right for
Locally Advanced or Metastatic Urothelial Cell CarcinomaUrinary Bladder DiseaseUrological Diseases
Rainier Therapeutics 71
Testing effectiveness (Phase 2)Looking for participantsNCT06995677
What this trial is testing

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07827612
What this trial is testing

Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer

Who this might be right for
Urinary Bladder NeoplasmsUrologic NeoplasmsReceptor, Fibroblast Growth Factor, Type 3
Eli Lilly and Company 161
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07393373
What this trial is testing

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

Who this might be right for
Hypochondroplasia
QED Therapeutics, a BridgeBio company 135
Not applicableAvailableNCT07675057
What this trial is testing

Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Who this might be right for
Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company
Testing effectiveness (Phase 2)Active Not RecruitingNCT05544552
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Who this might be right for
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaSolid Tumor+11 more
Tyra Biosciences, Inc 310
Large-scale testing (Phase 3)Looking for participantsNCT07218380
What this trial is testing

Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Who this might be right for
Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 450
Next Page